Jiangbo Pharmaceuticals, Inc.(fka JGBO)

[walkman]

Other interesting notes/questions on call....

Although they did not give margins on product by product, I thought it was interesting that their margins on 2 drugs were 35% (I think they were Clarythromycin and Itopride - correct me if I am wrong please)

When asked if they were looking at other markets Elsa indicated that China is where they will get the best bang for their buck - they mentioned that they were present in 30 out of 32 regions/provinces

Sales on recently released OTC Baobaole in first month (December) were 15% more than expected.

Also regarding 2 drugs in final approval stage did Elsa intimate that they were only waiting for approval "stuff" like on product packaging? I think she also said that they expected to launch by end of fiscal 08?